Cigna Investments Inc. New lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 623 shares of the medical research company’s stock after selling 105 shares during the quarter. Cigna Investments Inc. New’s holdings in Bio-Rad Laboratories were worth $224,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC increased its stake in shares of Bio-Rad Laboratories by 12.7% in the 1st quarter. FMR LLC now owns 182,762 shares of the medical research company’s stock valued at $55,867,000 after purchasing an additional 20,560 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Bio-Rad Laboratories by 13.6% in the 2nd quarter. Royal Bank of Canada now owns 6,677 shares of the medical research company’s stock valued at $2,086,000 after purchasing an additional 798 shares in the last quarter. BlackRock Inc. increased its stake in shares of Bio-Rad Laboratories by 1.2% in the 2nd quarter. BlackRock Inc. now owns 1,950,805 shares of the medical research company’s stock valued at $609,803,000 after purchasing an additional 22,263 shares in the last quarter. Valeo Financial Advisors LLC purchased a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $40,000. Finally, Meeder Asset Management Inc. increased its stake in shares of Bio-Rad Laboratories by 321.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 590 shares of the medical research company’s stock valued at $197,000 after purchasing an additional 450 shares in the last quarter. Hedge funds and other institutional investors own 63.94% of the company’s stock.
Shares of Bio-Rad Laboratories stock opened at $403.63 on Friday. The company has a quick ratio of 3.36, a current ratio of 4.72 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories, Inc. has a twelve month low of $262.38 and a twelve month high of $404.83. The business has a 50-day moving average price of $373.40 and a 200 day moving average price of $351.70. The firm has a market cap of $11.36 billion, a PE ratio of 53.06, a P/E/G ratio of 2.84 and a beta of 1.16.
Several equities analysts recently weighed in on the company. Citigroup assumed coverage on Bio-Rad Laboratories in a research note on Monday, January 6th. They issued a “buy” rating and a $450.00 price target for the company. Wells Fargo & Co lifted their price target on Bio-Rad Laboratories from $430.00 to $440.00 and gave the company an “overweight” rating in a research note on Friday. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $400.83.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Read More: Treasury Bonds
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.